GLP‐1 agonists vs placebo
PD motor impairment · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 60 participantsLow
Findings
What do systematic reviews say?
8 questions · 8 findings · 1 reviews · Movement Disorders
No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 4 · 50%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%
GLP‐1 agonists vs placebo
Health‐related quality of life · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 60 participantsLow
GLP‐1 agonists vs placebo
Serious adverse events · adults with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
GLP‐1 agonists vs placebo
Adverse events ‐ weight loss · adults with Parkinson's disease
GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).
1 finding from 1 review
- RR 1.25 [0.89, 1.76]1 study · 60 participantsLow
GLP‐1 agonists vs no treatment
PD motor impairment · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 44 participantsVery low
GLP‐1 agonists vs no treatment
Health‐related quality of life · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 44 participantsVery low
GLP‐1 agonists vs no treatment
Serious adverse events. · adults with Parkinson's disease
It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).
1 finding from 1 review
- RR 1.6 [0.4, 6.32]1 study · 44 participantsVery low
GLP‐1 agonists vs no treatment
Adverse events ‐ weight loss · adults with Parkinson's disease
1 finding from 1 review
- no estimate extracted1 study · 44 participantsVery low